Statement: There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts.
Primary_evidence: Adverse Events 1:   Total: 3/5 (60.00%)   Febrile neutropenia 3/5 (60.00%)   Atrial fibrillation 0/5 (0.00%)   Myocardial Infarction 0/5 (0.00%)   Blurred Vision 0/5 (0.00%)   Dysphagia 0/5 (0.00%)   Fever 0/5 (0.00%)   General disorders and administration site conditions - Other 0/5 (0.00%)   Localized edema 0/5 (0.00%)   Non-cardiac chest pain 0/5 (0.00%)   Pain 0/5 (0.00%)   Sepsis 0/5 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 17/110 (15.45%)   Hemoglobin  [1]1/110 (0.91%)   Esophagitis 1/110 (0.91%)   Dysphagia 1/110 (0.91%)   Nausea/Vomiting 1/110 (0.91%)   Nausea 1/110 (0.91%)   Fever 1/110 (0.91%)   Febrile Neutropenia 11/110 (10.00%)   Infection - Other  [2]1/110 (0.91%)   Infection - Pneumonia 1/110 (0.91%)   Dyspnea 2/110 (1.82%)   Hypoxia 1/110 (0.91%)